SAN DIEGO, June 27, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the kidneys. Over time, the painful, growing cysts rob the organs of their ...
MIT researchers including Robert Croy (left) and Bogdan Fedeles have discovered that a drug they originally developed as a potential cancer treatment may also hold promise in treating autosomal ...
SAN DIEGO, Sept. 20, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...
Patients receiving 300 mg farabursen demonstrated a mean halting of height-adjusted total kidney volume (htTKV) growth over 4 months Exploratory analysis of patients from high-dose cohorts ...
Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function. The disease affects more than 12 ...
A compound originally developed as a cancer treatment may hold promise for treating polycystic kidney disease (ADPKD), which affects more than half a million Americans and can lead to kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results